US Drug Pricing Reforms: ASCO Hears About Bargaining Chips And Baby Steps
Executive Summary
Former long-time congressional health staffer Rodney Whitlock discusses the status of prescription drug pricing reform policies in the administration and congress at the American Society for Clinical Oncology annual meeting.
You may also be interested in...
Price Arbitration In Medicare: MedPAC Supportive But Congress Running Out Of Time
In its June report to Congress, the Medicare Payment Advisory Commission expands upon previous recommendations for establishing a binding arbitration process to control drug prices in Medicare.
House Vs. Senate Drug Pricing Bills: A Snapshot Of Differences
Senate and House will likely have to reconcile differences on drug pricing legislation as Senate HELP Committee seeks public comment on a discussion draft.
New Payment Models For Curative Treatments Have CMS’ Attention, Verma Says
US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.